1 day+0.88%
6 months+0.88%
Current year+28.78%
Current year 0.88
Extreme 0.884
1.2
1 year 0.84
Extreme 0.835
1.2
3 years 0.72
Extreme 0.721
11.3
5 years 0.72
Extreme 0.721
56.4
10 years 0.72
Extreme 0.721
200
Date Insider Type Main position Quantity % Market Cap. Importance
8/19/25 Sell

Chief Executive Officer

25,172 0.2607%
7/22/25 Sell

Chief Executive Officer

29,176 0.3022%
7/22/25 Sell

Chief Financial Officer

13,609 0.1410%
Change 5-day change 1-year change 3-year change Capi.($)
+0.88%-.--% - - 14.79M
-4.83%+2.88%+55.87%+69.12% 69.4B
+0.02%+1.07%+10.63%+76.66% 57.24B
-1.19%+3.10%+24.94%+100.42% 57.62B
+2.21%+0.45%+27.35%+35.35% 43.65B
+5.01%+10.06%+22.64%+107.81% 44.03B
+7.18%-2.12%+205.06%+769.29% 38.08B
-1.86%+11.46%+26.67%+61.40% 36.31B
-2.97%-9.84%+88.86%+76.17% 32.61B
-2.18%+5.68%+36.21%-0.69% 25.47B
Average +0.23%+2.24%+55.36%+143.95% 44.93B
Weighted average by Cap. -0.08%+2.44%+51.21%+136.62%
Logo HOOA PHARPAR
HOOKIPA Pharma Inc. is a clinical-stage biopharmaceutical company developing a new class of immunotherapeutics based on its proprietary arenavirus platform that is designed to target and amplify T cell and immune responses to fight diseases. The Company's replicating and non-replicating technologies are engineered to induce robust and durable antigen-specific CD8+ T cell responses and pathogen-neutralizing antibodies. The Company is also engaged in the assessment of strategic alternatives and the development of infectious disease therapies in partnership with other companies. Its Hepatitis B (HBV) program, HB-400, and its Human Immunodeficiency Virus (HIV) program, HB-500, are developed in a partnership with Gilead Sciences Inc.
Employees
85
  1. Stock Market
  2. Stocks
  3. HOOK Stock